Attention Regeneron Pharmaceuticals Investors: Important Information Regarding a Securities Class Action Lawsuit
New York, NY – Rosen Law Firm, a global investor rights law firm, is reminding investors of their potential eligibility to participate in a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN). The lawsuit alleges that Regeneron and certain of its executives made false and/or misleading statements and/or failed to disclose material information during the period from November 2, 2023 to October 30, 2024 (the “Class Period”).
What Happened?
According to the complaint, the defendants made false and/or misleading statements and/or failed to disclose that:
- There were issues with the clinical trials for one of Regeneron’s drugs;
- The drug’s regulatory approval was uncertain;
- Regeneron’s financial results were negatively impacted by the aforementioned issues.
Who Can Participate?
If you purchased or otherwise acquired Regeneron securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline for this lawsuit is March 10, 2025.
What Does This Mean for Me?
If you are a Regeneron investor and you purchased your shares during the Class Period, you may be able to recover your losses through this lawsuit. It’s important to note that investing in securities always comes with risk, and it’s essential to do your due diligence before making investment decisions. In this case, if the allegations in the lawsuit are proven true, investors who purchased Regeneron securities during the Class Period may be able to recover their losses.
What Does This Mean for the World?
The outcome of this lawsuit could have significant implications for the biotech industry as a whole. If the allegations in the lawsuit are proven true, it could lead to increased scrutiny and regulation of clinical trials, as well as potential changes in how companies report financial results. Additionally, it could deter investors from putting their money into biotech stocks, leading to a potential downturn in the industry.
Conclusion
If you purchased Regeneron securities during the Class Period and believe you may be entitled to compensation, it’s important to act quickly. The lead plaintiff deadline for this lawsuit is March 10, 2025. Contact Rosen Law Firm for more information about your potential eligibility and how to participate in the lawsuit.
Regeneron investors should be aware that investing in securities always carries risk. It’s essential to do your due diligence and stay informed about the companies you invest in. In this case, the outcome of the lawsuit could have significant implications for the biotech industry and the investing community as a whole.
As a reminder, if you have any questions or concerns about this lawsuit or your potential eligibility, please do not hesitate to contact Rosen Law Firm for a free consultation.
